Peer-Reviewed Journal Details
Mandatory Fields
Diaz, ACD;Malone, K;Shearer, JA;Moore, AC;Waeber, C
2021
June
Data In Brief
Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE(-/-) mice in the presence and absence of immunomodulation with fingolimod
Validated
WOS: 1 ()
Optional Fields
MODELS
36
In this work, the sphingosine-1-phosphate receptor modulator fingolimod was assessed as a preclinical candidate for the treatment of acute ischaemic stroke according to the Stroke Therapy Academic Industry Roundtable (STAIR) preclinical recommendations. Young (15-17 weeks), aged (7273 weeks), and ApoE(-/-) mice (20-21 weeks) fed a high fat diet (all C57BL/6 mice) underwent permanent electrocoagulation of the left middle cerebral artery. Mice received either saline or fingolimod (0.5 mg/kg or 1 mg/kg) at 2-, 24-, and 48-hours post-ischaemia via intraperitoneal (i.p.) injection. Another cohort of young mice (8-9 and 17-19 weeks) received short-term (5 days) or long-term (10 days) fingolimod (0.5 mg/kg) treatment in a treatment duration study. For young, aged, and ApoE(-/-) mice, motor behavioural tests (cylinder and grid-walking) were performed at days 0, 3, and 7 post-ischaemia to evaluate neurobehavioural recovery. In the treatment duration study, the grid-walking test was performed at days 0, 2, 5 and 10 post-ischaemia. Brain tissue sections were stained with haematoxylin and eosin (H&E), and NeuN to quantify tissue damage. Flow cytometry was used to quantify T cell populations in blood, spleen, and lymph nodes. The data presented in this article improves our understanding of the potential neuroprotective and immunomodulatory effects of fingolimod in a mouse model of brain ischaemia. Such data may be significant in the design of future preclinical and clinical stroke studies for fingolimod. (C) 2021 The Author(s). Published by Elsevier Inc.
AMSTERDAM
2352-3409
10.1016/j.dib.2021.107146
Grant Details